Essential Therapeutics Inc. on Friday said it will strengthen its clinical and preclinical pipeline through the acquisition of Maret Pharmaceuticals Inc. in a deal valued at up to about $6.8 million. (BioWorld Today)

Essential Acquiring Maret For 2M Shares Of Locked-Up Stock

March 4, 2002

By Kim Coghill

FDA Panel Agrees To Corixa’s Melacine Phase III Study Protocol

March 1, 2002

By Kim Coghill

FDA Panel Agrees To Corixa’s Melacine Phase III Study Protocol

March 1, 2002

By Kim Coghill

Inhale Strikes Three Deals For PEG Technology, One On THC

Feb. 27, 2002

By Kim Coghill

Inhale Therapeutic Systems Inc. said Tuesday that it recently signed three collaboration deals for use of its PEG injectable technology, and a fourth using its pulmonary technology. (BioWorld Today)

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...